Fibrocell Announces Completion of Public Offering of Common Stock

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced that it has completed its previously announced underwritten public offering of 11,000,000 shares of common stock at a public offering price of $4.10 per share. The net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, were approximately $42.1 million.